CytomX Therapeutics, Inc.
CTMX· Nasdaq
CTMXCytomX Therapeutics, Inc.
Filed Aug 3, 2016 · 10-Q · 34 days after period end · 0001564590-16-022364
| Metric | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|
| Revenue | $3.09M | $2.04M | $666.00K |
| Net Income | -$14.18M | -$5.81M | -$4.93M |
| EPS Diluted | -$0.39 | -$7.56 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Aug 3, 2016 · 34 d after period end
